The long-term development trajectory of the global Adenosine Deaminase Deficiency Therapeutic Market is being defined by substantial clinical evolution and evolving public healthcare policies. Severe combined immunodeficiency caused by ADA mutations requires immediate, highly coordinated clinical management to prevent catastrophic systemic infections. In response, global regulatory authorities...